By Mano 
Mounjaro costs vary considerably in Australia depending on the dose strength and pharmacy. Published Chemist Warehouse listings checked in September 2026 range from A$279.99 to A$689.99 for one KwikPen containing four weekly doses. That is a four-week medicine cost, not a fixed national monthly price.
For a single four-dose Mounjaro KwikPen, the published prices were A$279.99 for 2.5 mg, A$389.99 for 5 mg, A$539.99 for 7.5 mg, A$539.99 for 10 mg, A$689.99 for 12.5 mg, and A$689.99 for 15 mg.
These figures are useful as a current pharmacy reference, but they should not be treated as an Australia-wide fixed price. Private prescription prices can differ between pharmacies and can change over time.
There is another detail worth noticing: a KwikPen contains four weekly doses, so its price represents approximately four weeks of medicine. Four weeks is 28 days, which is slightly shorter than an average calendar month. This is one reason different websites can give apparently different “monthly” Mounjaro costs.
For weight management, Mounjaro is not currently PBS-subsidised. The Pharmaceutical Benefits Advisory Committee states that the sponsor of tirzepatide has not submitted it for PBS listing for the treatment of overweight or obesity. People using a GLP-1 medicine for weight loss therefore currently pay the medicine cost themselves rather than receiving a PBS weight-management subsidy.
PBS status is worth checking again whenever this article is updated because government funding decisions can change.
The pharmacy price is not necessarily the complete cost of treatment. A GP or telehealth consultation may be charged separately, and some services may also have delivery or other service fees.
The dose strength can also affect the medicine price. However, dose selection should be based on clinical assessment, response and tolerability—not on which pen costs less. Changing a prescription or dose to reduce expenditure is a medical decision to discuss with the prescriber.
When comparing prices online, check whether the figure refers to medicine only or to a package that includes consultations, delivery or ongoing support. Comparing those as though they were identical can produce misleading cost estimates.
Yes. Healthdirect identifies Mounjaro as a Schedule 4 Prescription Only Medicine in Australia. A pharmacist cannot simply sell it as an over-the-counter weight-loss product.
Mounjaro contains tirzepatide. The TGA has approved it for chronic weight management in adults who meet specified BMI and health criteria, as well as for other registered indications. Approval for an indication does not mean the medicine is appropriate for every individual; suitability should be assessed by a qualified prescriber.
For medicine alone, current published pharmacy examples put a four-dose pen at roughly A$280 to A$690, depending on strength. Your actual cost may be different if the pharmacy changes its price or if consultation, dispensing, delivery or other service costs apply.
Rather than relying on an old “monthly price,” check the current price for the exact strength on your prescription and ask what other fees are included.
No. It is a useful published pharmacy example, not a government-set national private price. Other pharmacies may charge differently.
Different KwikPen strengths can have different private retail prices. The published examples above show several price tiers rather than one price across all strengths.
Cost should not determine your prescribed dose. Dose changes should be made with the clinician managing your treatment.
Prices checked: September 2026. Pharmacy prices and PBS arrangements can change, so current information should be reconfirmed before relying on a figure.
This article provides general information only and does not replace individual medical advice. For other independently researched topics, browse our Health section.